WHO Expands Emergency Use Listing for Mpox Diagnostic Tests

The World Health Organization has expanded its Emergency Use Listing by adding two new mpox in-vitro diagnostic tests. The tests include Xpert Mpox by Cepheid and the cobas MPXV assay by Roche. These PCR-based tests are aimed at enhancing mpox detection and response capabilities.

The World Health Organization recently updated its Emergency Use Listing, introducing two new mpox diagnostic tests. This move is aimed at boosting global response efforts for mpox through enhanced detection.

On October 25, the Xpert Mpox, a real-time PCR test manufactured by Cepheid, was officially listed under the Emergency Use Listing procedure. This marks a crucial step in the fight against mpox, as effective detection is imperative for timely responses.

Additionally, WHO included another PCR-based diagnostic option, the cobas MPXV assay by Roche Molecular Systems, on October 14. These advancements underscore WHO's commitment to fortifying public health measures against mpox.

(With inputs from agencies.)